Batefenterol Succinate  (Synonyms: GSK961081 Succinate; TD-5959 Succinate)

Batefenterol Succinate (GSK961081 Succinate) is a first-of-its-kind inhaled bifunctional bronchodilator with smooth muscle relaxant properties. The activities of Batefenterol Succinate include acting as a smooth muscle parasympathetic antagonist and a beta2-adrenoceptor agonist. Batefenterol Succinate is used to improve respiratory function, especially in patients with chronic obstructive pulmonary disease (COPD)^[1].

858.33

C₄₄H₄₈ClN₅O₁₁

945905-37-3

OC(CCC(O)=O)=O.COC(C=C(C(Cl)=C1)NC(CCN2CCC(CC2)OC(NC3=C(C4=CC=CC=C4)C=CC=C3)=O)=O)=C1CNC[C@@H](C5=C6C(NC(C=C6)=O)=C(C=C5)O)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hegde SS, et al. Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties. J Pharmacol Exp Ther. 2014 Oct;351(1):190-9.  [Content Brief]

  [2]. Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD  [Content Brief]

  [3]. Hughes AD, et al. Discovery of (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, batefenterol): first-in-class dual pharmacology multivalent muscarinic antagonist and β? agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD). J Med Chem. 2015 Mar 26;58(6):2609-22.  [Content Brief]